subpage banner


Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases

What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar?

MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar?

This year due to the impact of the COVID-19 pandemic, the Michael J. Fox Foundation (MJFF) has elected to hold their annual 2021 Parkinson’s Disease Therapeutics Conference virtually through a webinar series. Gain Therapeutics will be presenting at the MJFF Parkinson’s Disease Therapeutics Webinar on November 10th, 2021. You can read more about the history of the conference here

In September of this year, Gain Therapeutics released positive topline data in a patient-iPSC study done evaluating the companies STAR compounds for the treatment of Parkinson’s disease. The study done in the lab of Professor Ricardo Feldman at the University of Maryland School of Medicine, showed very promising results including the potential for the reversal of neurodegeneration. The topline data was released in a company press release which can be read here

MJFF 2021 Conference Schedule:

MJFF 2021 Conference Schedule Day 1 November 9 2021 300x273

MJFF 2021 Conference Schedule day 2 November 10 2021 300x293

MJFF Parkinson’s Disease 2021 Therapeutics Webinars – Register Here

At the virtual webinar Gain Therapeutics will be releasing the full dataset along with some additional data. Marco Baptista PhD, Vice President of Research Programs at MJFF, said “these encouraging results show promise for this approach to correct dysfunction in the GBA1 pathway, a leading target for Parkinson’s drug development.” Presenting the full dataset at this webinar is a great opportunity for the company to not only update the biopharmaceutical community on the progress being made in the program, but also to potentially form a partnership with a company as Gain looks to move the program into clinical studies. 

The company’s program targeting GBA Parkinson’s disease has been funded by the Michael J. Fox Foundation, since March of 2019. To learn more about the webinar or to register, please click here



Latest Articles